Effect of IVIG administration on complement activation and HLA antibody levels

ORIGINAL ARTICLE

Takafumi MacHimoto, Giselle Guerra, George W Burke, Frederick Jay Fricker, Jane Colona, Phillip Ruiz, Herwig Ulf Meier-Kriesche, Juan Scornik

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The objective of the present study was to determine if there are changes on complement (C) activation and concentration of HLA antibodies (Abs) in patients treated with intravenous immunoglobulin (IVIG). The patients evaluated were given IVIG as treatment of Ab-mediated rejection or desensitization. The patients' sera obtained before and after IVIG administration were tested for their effects on the deposition of both IgG (HLA Abs) and C3b (C activation) as measured by flow cytometry on T cells. IVIG consistently inhibited C activation when measured shortly after IVIG infusion but returned to the initial levels at 2-4 weeks, when total serum IgG also returned to pre-infusion levels. C inhibition was more pronounced with higher IVIG doses and the degree of inhibition was inversely proportional to the HLA Ab concentrations. IVIG did not block the binding of HLA Abs immediately after administration, although levels were slightly but consistently lower after several monthly IVIG infusions. The data show that C inhibition by IVIG is short-lived and that IVIG induces only a mild reduction of HLA Abs, seen not immediately but after months of treatment. These results may explain the inconsistent results of IVIG to achieve desensitization.

Original languageEnglish
Pages (from-to)1015-1022
Number of pages8
JournalTransplant International
Volume23
Issue number10
DOIs
StatePublished - Oct 1 2010

Fingerprint

Complement Activation
Intravenous Immunoglobulins
Intravenous Administration
Antibodies
Intravenous Infusions
Immunoglobulin G
Serum
Flow Cytometry
T-Lymphocytes

Keywords

  • complement
  • HLA antibodies
  • intravenous immunoglobulin

ASJC Scopus subject areas

  • Transplantation

Cite this

Effect of IVIG administration on complement activation and HLA antibody levels : ORIGINAL ARTICLE. / MacHimoto, Takafumi; Guerra, Giselle; Burke, George W; Fricker, Frederick Jay; Colona, Jane; Ruiz, Phillip; Meier-Kriesche, Herwig Ulf; Scornik, Juan.

In: Transplant International, Vol. 23, No. 10, 01.10.2010, p. 1015-1022.

Research output: Contribution to journalArticle

MacHimoto, Takafumi ; Guerra, Giselle ; Burke, George W ; Fricker, Frederick Jay ; Colona, Jane ; Ruiz, Phillip ; Meier-Kriesche, Herwig Ulf ; Scornik, Juan. / Effect of IVIG administration on complement activation and HLA antibody levels : ORIGINAL ARTICLE. In: Transplant International. 2010 ; Vol. 23, No. 10. pp. 1015-1022.
@article{137895bbccf84c5b8c0efe255c8e4189,
title = "Effect of IVIG administration on complement activation and HLA antibody levels: ORIGINAL ARTICLE",
abstract = "The objective of the present study was to determine if there are changes on complement (C) activation and concentration of HLA antibodies (Abs) in patients treated with intravenous immunoglobulin (IVIG). The patients evaluated were given IVIG as treatment of Ab-mediated rejection or desensitization. The patients' sera obtained before and after IVIG administration were tested for their effects on the deposition of both IgG (HLA Abs) and C3b (C activation) as measured by flow cytometry on T cells. IVIG consistently inhibited C activation when measured shortly after IVIG infusion but returned to the initial levels at 2-4 weeks, when total serum IgG also returned to pre-infusion levels. C inhibition was more pronounced with higher IVIG doses and the degree of inhibition was inversely proportional to the HLA Ab concentrations. IVIG did not block the binding of HLA Abs immediately after administration, although levels were slightly but consistently lower after several monthly IVIG infusions. The data show that C inhibition by IVIG is short-lived and that IVIG induces only a mild reduction of HLA Abs, seen not immediately but after months of treatment. These results may explain the inconsistent results of IVIG to achieve desensitization.",
keywords = "complement, HLA antibodies, intravenous immunoglobulin",
author = "Takafumi MacHimoto and Giselle Guerra and Burke, {George W} and Fricker, {Frederick Jay} and Jane Colona and Phillip Ruiz and Meier-Kriesche, {Herwig Ulf} and Juan Scornik",
year = "2010",
month = "10",
day = "1",
doi = "10.1111/j.1432-2277.2010.01088.x",
language = "English",
volume = "23",
pages = "1015--1022",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Effect of IVIG administration on complement activation and HLA antibody levels

T2 - ORIGINAL ARTICLE

AU - MacHimoto, Takafumi

AU - Guerra, Giselle

AU - Burke, George W

AU - Fricker, Frederick Jay

AU - Colona, Jane

AU - Ruiz, Phillip

AU - Meier-Kriesche, Herwig Ulf

AU - Scornik, Juan

PY - 2010/10/1

Y1 - 2010/10/1

N2 - The objective of the present study was to determine if there are changes on complement (C) activation and concentration of HLA antibodies (Abs) in patients treated with intravenous immunoglobulin (IVIG). The patients evaluated were given IVIG as treatment of Ab-mediated rejection or desensitization. The patients' sera obtained before and after IVIG administration were tested for their effects on the deposition of both IgG (HLA Abs) and C3b (C activation) as measured by flow cytometry on T cells. IVIG consistently inhibited C activation when measured shortly after IVIG infusion but returned to the initial levels at 2-4 weeks, when total serum IgG also returned to pre-infusion levels. C inhibition was more pronounced with higher IVIG doses and the degree of inhibition was inversely proportional to the HLA Ab concentrations. IVIG did not block the binding of HLA Abs immediately after administration, although levels were slightly but consistently lower after several monthly IVIG infusions. The data show that C inhibition by IVIG is short-lived and that IVIG induces only a mild reduction of HLA Abs, seen not immediately but after months of treatment. These results may explain the inconsistent results of IVIG to achieve desensitization.

AB - The objective of the present study was to determine if there are changes on complement (C) activation and concentration of HLA antibodies (Abs) in patients treated with intravenous immunoglobulin (IVIG). The patients evaluated were given IVIG as treatment of Ab-mediated rejection or desensitization. The patients' sera obtained before and after IVIG administration were tested for their effects on the deposition of both IgG (HLA Abs) and C3b (C activation) as measured by flow cytometry on T cells. IVIG consistently inhibited C activation when measured shortly after IVIG infusion but returned to the initial levels at 2-4 weeks, when total serum IgG also returned to pre-infusion levels. C inhibition was more pronounced with higher IVIG doses and the degree of inhibition was inversely proportional to the HLA Ab concentrations. IVIG did not block the binding of HLA Abs immediately after administration, although levels were slightly but consistently lower after several monthly IVIG infusions. The data show that C inhibition by IVIG is short-lived and that IVIG induces only a mild reduction of HLA Abs, seen not immediately but after months of treatment. These results may explain the inconsistent results of IVIG to achieve desensitization.

KW - complement

KW - HLA antibodies

KW - intravenous immunoglobulin

UR - http://www.scopus.com/inward/record.url?scp=77956326085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956326085&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2010.01088.x

DO - 10.1111/j.1432-2277.2010.01088.x

M3 - Article

VL - 23

SP - 1015

EP - 1022

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 10

ER -